- £1.99bn
- £1.05bn
- $630.20m
- 23
- 44
- 41
- 24
REG - Hutchmed China Ltd - Appointment of Independent Non-executive Director
AnnouncementRCS - Hutchmed China Ltd - Data to be Presented at the 2025 ESMO Congress
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Highlights Data to be Presented at ESMO
AnnouncementREG - Hutchmed China Ltd - Total Voting Rights
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED to Present R&D Updates on October 31 2025
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Highlights Data to be Presented at CSCO
AnnouncementREG - Hutchmed China Ltd - Directorate Change
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Completes Enrollment of Phase III Trial
AnnouncementREG - Hutchmed China Ltd - 2025 Interim Results
AnnouncementREG - Hutchmed China Ltd - HUTCHMED to Announce 2025 Half-Year Results
AnnouncementREG - Hutchmed China Ltd - Update on Joint Corporate Brokers in London
AnnouncementREG - Hutchmed China Ltd - Total Voting Rights
AnnouncementREG - Hutchmed China Ltd - China Approval based on Phase III SACHI Trial
AnnouncementREG - Hutchmed China Ltd - Blocklisting Six Monthly Return
AnnouncementREG - Hutchmed China Ltd - Grant of Share Options and Awards under LTIP
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED and Innovent Announce NDA Acceptance
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Highlights SACHI Phase III Data at ASCO
AnnouncementREG - Hutchmed China Ltd - Total Voting Rights
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Highlights Data to be Presented at ASCO
Announcement